Victoria, British Columbia Thursday, November 14, 2024, 18:00 Hrs [IST] ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals is hosting a webinar on November 15, 2024, focusing on Eosinophilic Esophagitis, a rapidly growing digestive ...

Eupraxia Pharmaceuticals (EPRX)announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic ...

Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.

Within two days of the election, Newsom positioned himself at the forefront of the opposition, calling for state lawmakers to convene an emergency special session "to safeguard California values" in ...

A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...